Study Results Show Investigational Drug, Prasugrel, Cuts Risk Of Stent-Related Clots By More Than Half Versus Clopidogrel The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) - a major concern for physicians and patients with potentially fatal consequences - in patients who received a stent as compared to standard therapy with clopidogrel (Plavix(R)) plus aspirin (1.13 percent vs. 2.
Source: www.medicalnewstoday.comIPods Found Not To Affect Pacemaker Function, Contrary To Prior Reports Last May, a widely reported study concluded that errant electronic noise from iPods can cause implantable cardiac pacemakers to malfunction. This just didn't sound right to the cardiac electrophysiologists at Children's Hospital Boston, who've seen hundreds of children, teens and young adults with heart conditions requiring pacemakers.
Source: www.medicalnewstoday.comTAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates In Diabetic Patients Compared To Non Diabetics In ARRIVE 1 And 2 Registries Boston Scientific Corporation (NYSE: BSX) announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice.
Source: www.medicalnewstoday.comStudy Finds Improvement In The Care Of Children With Cancer At The End Of Life Expanded use of palliative care services is associated with enhanced communications between families and caregivers, improved symptoms management, and better quality of life for children dying from cancer, according to study by researchers at Dana-Farber Cancer Institute and Children's Hospital Boston.
Source: www.medicalnewstoday.comISAR-REACT 3 Pits Bivalirudin Vs. Unfractionated Heparin In PCI A large randomized trial will shed light on the ideal combination of medications for preventing unwanted blood clotting during and shortly after percutaneous coronary intervention (PCI).
Source: www.medicalnewstoday.comPharsight Invited To Present On HIV Modeling And Simulation At ASCPT Annual Meeting Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, announced that Bill Poland, Ph.D.
Source: www.medicalnewstoday.comTailored Clopidogrel Dosing Improves PCI Outcomes Using a simple blood test to individualize the loading dose of a medication that prevents blood clotting significantly reduces the risk of major cardiovascular complications after percutaneous coronary interventions (PCI), according to a multicenter study reported in a Late-Breaking Clinica
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
